TP53 and neoplasm: These data are consistent with a model in which the strength of signaling induced by these oncogenic Kras variants in vivo is insufficient to engage the p53 pathway; thus, while p53 functions to constrain tumor progression, it does not appear to limit the initial expansion of tumors with different Kras genotypes49.